Semaglutide vs Tirzepatide vs Retatrutide: Which Weight Loss Peptide Wins in UAE? (2026)
Semaglutide vs Tirzepatide vs Retatrutide: Which Weight Loss Peptide Wins in UAE? (2026)
Three generations of GLP-based weight loss peptides are now available in the UAE. Each generation adds a new receptor target — producing progressively greater weight loss at the cost of greater complexity. This head-to-head comparison gives UAE-based researchers and patients everything they need to understand the differences.
Quick Comparison Table
| Property | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro) | Retatrutide (Triple G) |
|---|---|---|---|
| Receptor targets | GLP-1R only | GLP-1R + GIPR | GLP-1R + GIPR + Glucagon R |
| Generation | 1st | 2nd | 3rd (investigational) |
| Max weight loss (trials) | ~15% (STEP 1) | ~22.5% (SURMOUNT-1) | ~24% (Phase II) |
| Dosing | Once weekly SC | Once weekly SC | Once weekly SC |
| FDA approval | Yes (Wegovy obesity 2021) | Yes (Zepbound obesity 2023) | No (Phase III ongoing) |
| Half-life | ~7 days | ~5 days | ~6 days |
Mechanism Differences: What Each Receptor Adds
GLP-1 Receptor (all three)
The foundation of all three drugs. GLP-1R agonism suppresses appetite via hypothalamic arcuate nucleus signalling, slows gastric emptying (prolonging satiety), and stimulates insulin secretion in a glucose-dependent manner. Responsible for ~10-12% weight loss when used alone.
GIP Receptor (Tirzepatide + Retatrutide)
Adding GIPR agonism to GLP-1R produces weight loss approximately 50% greater than GLP-1 alone (22.5% vs 15%). The mechanism is counterintuitive: at physiological levels, GIP promotes fat storage — but at pharmacological doses combined with GLP-1, GIPR activation enhances energy expenditure and fat mobilisation via central mechanisms. It also reduces GLP-1-induced nausea by acting on the area postrema.
Glucagon Receptor (Retatrutide only)
Glucagon receptor agonism adds thermogenesis — increasing basal metabolic rate — and promotes lipolysis in adipose tissue. This provides the additional weight loss beyond dual agonism (~2-3% additional beyond tirzepatide-equivalent). However, it also increases the risk of hyperglycaemia and requires careful dose titration.
Weight Loss Results: The Clinical Data
- Semaglutide 2.4mg (STEP 1): 14.9% mean weight loss at 68 weeks vs 2.4% placebo — 37% of participants lost ≥20% body weight
- Tirzepatide 15mg (SURMOUNT-1): 22.5% mean weight loss at 72 weeks vs 2.5% placebo — 57% of participants lost ≥20% body weight
- Retatrutide 12mg (Phase II): ~24% mean weight loss at 48 weeks — with the dose-response curve suggesting even greater reductions with longer treatment. Phase III results pending.
Side Effect Comparison
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea/vomiting | Common (44%) | Less than sema (GIP effect) | Comparable to tirzepatide |
| Constipation | Moderate | Moderate | Moderate |
| Muscle loss | ~40% of weight loss | Similar | Similar (research ongoing) |
| Heart rate increase | Mild | Mild | Moderate (glucagon effect) |
| Hypoglycaemia | Low (glucose-dependent) | Low | Higher (glucagon involvement) |
Which Is Available in UAE?
- Tirzepatide (Mounjaro KwikPen): Available in UAE at authorised pharmacies and online. 10mg, 12.5mg, and 15mg pens available. Requires prescription from UAE-licensed physician.
- Semaglutide: Available through UAE pharmacies (Ozempic for diabetes, Wegovy for obesity). Supply has been intermittent due to global demand.
- Retatrutide: Not FDA-approved. Available as research-grade peptide (Triple G) for research purposes.
Related Products
Shop Weight Loss Peptides — Dubai & UAE
Tirzepatide KwikPen, Retatrutide (Triple G), and AOD9604 — all available with same-week shipping.
Shop NowFAQ
Clinical trial data consistently shows tirzepatide achieves greater weight loss (22.5% vs 15%) with comparable or better tolerability at equivalent stages of treatment. For weight loss as the primary goal, tirzepatide is the superior option based on current evidence.
Retatrutide (Eli Lilly) is in Phase III trials as of 2026. FDA approval is anticipated no earlier than 2027–2028 if Phase III data confirms Phase II results. It is currently available only as a research compound.
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Disclaimer: This article is for educational and research purposes only. All products mentioned are research compounds or investigational drugs not approved for general human therapeutic use in UAE. Consult a licensed UAE healthcare professional before beginning any protocol.
Written by Core Sup Research Team
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: April 2026 · About Core Sup
